All of the following statements about the new product Dyanavel XR (amphetamine 5 mg, 10 mg, 15 mg and 20 mg extended-release tablets) for treatment of attention deficit hyperactivity disorder are true, EXCEPT for . . .
A pharmacist avoids a potentially harmful dosing error after recognizing that different strengths of a combination drug were not directly interchangeable.